JP2017176174A5 - - Google Patents

Download PDF

Info

Publication number
JP2017176174A5
JP2017176174A5 JP2017057024A JP2017057024A JP2017176174A5 JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5 JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
region
same amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017057024A
Other languages
English (en)
Other versions
JP6392923B2 (ja
JP2017176174A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017176174A publication Critical patent/JP2017176174A/ja
Publication of JP2017176174A5 publication Critical patent/JP2017176174A5/ja
Application granted granted Critical
Publication of JP6392923B2 publication Critical patent/JP6392923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (1)

  1. ＭＵＣ１＊に対する単離された一価又は二価のモノクローナル抗体であって、
    配列番号１のアミノ酸配列に特異的に結合するものであり、
    （ａ）
    重鎖可変領域のアミノ酸配列が以下を含む：
    ＣＤＲ１領域において、配列番号１７２と同一のアミノ酸配列、
    ＣＤＲ２領域において、配列番号１９８と同一のアミノ酸配列、及び
    ＣＤＲ３領域において、配列番号２２４と同一のアミノ酸配列、及び
    軽鎖可変領域のアミノ酸配列が以下を含む：
    ＣＤＲ１領域において、配列番号１０８と同一のアミノ酸配列、
    ＣＤＲ２領域において、配列番号１２９と同一のアミノ酸配列、及び
    ＣＤＲ３領域において、配列番号１４９と同一のアミノ酸配列、又は
    （ｂ）
    重鎖可変領域のアミノ酸配列が以下を含む：
    ＣＤＲ１領域において、配列番号１７３と同一のアミノ酸配列、
    ＣＤＲ２領域において、配列番号１９９と同一のアミノ酸配列、及び
    ＣＤＲ３領域において、配列番号２２５と同一のアミノ酸配列、及び
    軽鎖可変領域のアミノ酸配列が以下を含む：
    ＣＤＲ１領域において、配列番号１０９と同一のアミノ酸配列、
    ＣＤＲ２領域において、配列番号１３０と同一のアミノ酸配列、及び
    ＣＤＲ３領域において、配列番号１５０と同一のアミノ酸配列、
    を含む、モノクローナル抗体。
JP2017057024A 2008-10-06 2017-03-23 Ｍｕｃ１＊抗体 Active JP6392923B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10320408P 2008-10-06 2008-10-06
US61/103,204 2008-10-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014226709A Division JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体

Publications (3)

Publication Number Publication Date
JP2017176174A JP2017176174A (ja) 2017-10-05
JP2017176174A5 true JP2017176174A5 (ja) 2017-11-16
JP6392923B2 JP6392923B2 (ja) 2018-09-19

Family

ID=42101177

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011531128A Pending JP2012504961A (ja) 2008-10-06 2009-10-06 Ｍｕｃ１＊抗体
JP2014226709A Active JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体
JP2017057024A Active JP6392923B2 (ja) 2008-10-06 2017-03-23 Ｍｕｃ１＊抗体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011531128A Pending JP2012504961A (ja) 2008-10-06 2009-10-06 Ｍｕｃ１＊抗体
JP2014226709A Active JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体

Country Status (8)

Country Link
US (4) US10421819B2 (ja)
EP (3) EP3130607B1 (ja)
JP (3) JP2012504961A (ja)
KR (1) KR101455447B1 (ja)
CN (1) CN102239182B (ja)
CR (1) CR20110238A (ja)
IL (1) IL212175B (ja)
WO (1) WO2010042562A2 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421819B2 (en) 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
KR20140101876A (ko) * 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP3524672A3 (en) * 2010-06-16 2019-12-18 Minerva Biotechnologies Corporation Reprogramming cancer cells
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
JP6196163B2 (ja) * 2011-03-17 2017-09-13 ミネルバ バイオテクノロジーズ コーポレーション 多能性幹細胞を作製する方法
CN102716472A (zh) * 2011-03-31 2012-10-10 李光辉 一种肿瘤疫苗及其合成方法
AU2013289913A1 (en) * 2012-07-13 2015-03-05 Minerva Biotechnologies Corporation Method for inducing cells to less mature state
JP6664219B2 (ja) * 2012-08-14 2020-03-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞増強治療法
CA2886161A1 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
EP2948472B1 (en) * 2013-01-23 2019-05-22 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
AU2015211034B2 (en) * 2014-01-29 2020-04-09 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
JP6927875B2 (ja) * 2014-09-16 2021-09-01 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｍｅｔ抗体および組成物
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
JP2017536091A (ja) 2014-10-02 2017-12-07 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 多価メディトープ、メディトープ結合性抗体およびそれらの使用
US9688750B2 (en) 2014-10-07 2017-06-27 Ann And Robert H. Lurie Children's Hospital Of Chicago Anti-nodal antibodies and methods of using same
US11746159B2 (en) 2015-02-10 2023-09-05 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CA3007646A1 (en) * 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
EP4245775A3 (en) * 2016-04-29 2023-11-15 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
JP2020514304A (ja) * 2017-01-27 2020-05-21 グリコトープ ゲーエムベーハー 抗ＭＵＣ１抗体およびＥｒｂＢ阻害剤を用いた抗がん処置
SG11201908813QA (en) * 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
CN109971713B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
AU2020205735A1 (en) * 2019-01-11 2021-08-05 Minerva Biotechnologies Corporation Anti-variable MUC1* antibodies and uses thereof
AU2021297535A1 (en) * 2020-06-26 2023-02-16 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
AU2021310499A1 (en) * 2020-07-16 2023-03-09 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
EP4188432A1 (en) * 2020-07-31 2023-06-07 R.P. Scherer Technologies, LLC Antibody specific for mucin-1 and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020136725A1 (en) * 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
CA2348781A1 (en) * 1998-11-12 2000-05-25 Novolytics Inc. Compositions and methods for producing vascular occlusion
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
AU2001267824A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cancer
KR20030068536A (ko) 2000-09-11 2003-08-21 다나-파버 캔서 인스티튜트 Ｍｕｃ1 세포외 도메인 및 이로부터 유래된 암 치료조성물과 방법
US7700715B2 (en) * 2000-11-27 2010-04-20 Minerva Biotechnologies Corporation Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
WO2005019269A2 (en) 2002-11-27 2005-03-03 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
US20050019324A1 (en) 2001-03-29 2005-01-27 Wreschner Daniel H. Peptides and antibodies to muc 1 proteins
US7630836B2 (en) 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
ATE469648T1 (de) 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
JP4354280B2 (ja) * 2002-03-01 2009-10-28 イミューノメディクス、インコーポレイテッド Ｒｓ７抗体
AU2003225009A1 (en) * 2002-04-22 2003-11-03 Dyax Corporation Antibodies specific for mucin polypeptide
ES2524767T3 (es) * 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060173171A1 (en) 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
DE602005018325D1 (de) * 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
KR101252306B1 (ko) * 2004-10-04 2013-04-08 제넨테크, 인크. 간세포 성장 인자 활성화제의 조정제
WO2006105448A2 (en) * 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
WO2008070171A2 (en) 2006-12-06 2008-06-12 Minerva Biotechnologies Corp. Method for identifying and manipulating cells
WO2008073817A2 (en) * 2006-12-08 2008-06-19 Dana-Farber Cancer Institute, Inc. Muc1 and galectin-3
US10421819B2 (en) 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
JP6664219B2 (ja) * 2012-08-14 2020-03-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞増強治療法

Similar Documents

Publication Publication Date Title
JP2017176174A5 (ja)
JP2018504907A5 (ja)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
JP2019524645A5 (ja)
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
JP2019528240A5 (ja)
JP2016185981A5 (ja)
JP2014205674A5 (ja)
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
JP2017114866A5 (ja)
JP2018021031A5 (ja)
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
PE20190737A1 (es) Anticuerpos anti-cd27
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2013539454A5 (ja)
AR105267A1 (es) Anticuerpos de unión a tau
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
JP2018537399A5 (ja)
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
WO2012047732A3 (en) Antibody compositions and methods of use